# Rigel Pharmaceuticals, Inc > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/en/companies/Rigel Pharmaceuticals, Inc). ## Overview Rigel Pharmaceuticals is a U.S.-based biotechnology company focused on therapies for hematologic disorders and cancer. Its business centers on developing, commercializing, and licensing small-molecule medicines, including TAVALISSE for chronic immune thrombocytopenia and REZLIDHIA for relapsed or refractory AML, with commercial activity in the United States and partnered markets outside the U.S. ## Products & services • TAVALISSE (fostamatinib) for chronic adult ITP • REZLIDHIA (olutasidenib) for IDH1-mutated AML • Global licensing and commercialization rights • Drug supply, royalties, and milestone revenue from partners • Patient support and reimbursement services via Rigel OneCare - **Commercial hematology products** (70%) — Approved medicines sold directly or through partners for blood disorders and leukemia. - **Licensed product collaborations** (25%) — Partnered commercialization, royalties, milestones, and drug supply tied to out-licensed assets. - **Government and research-related revenue** (5%) — Contract revenue tied to government-supported development or research programs. - TAVALISSE (fostamatinib) for chronic adult ITP - REZLIDHIA (olutasidenib) for IDH1-mutated AML - Global licensing and commercialization rights - Drug supply, royalties, and milestone revenue from partners - Patient support and reimbursement services via Rigel OneCare ## Customers Rigel sells primarily to hematologists and hematologist-oncologists in the U.S. who treat chronic adult ITP and AML patients. Its products also reach patients through specialty pharmacies, wholesalers, group purchasing organizations, and partner companies in ex-U.S. markets. For partnered products, the customer is often a pharmaceutical licensee that buys drug supply, pays royalties, or funds milestone-based collaboration arrangements. - **U.S. hematologists and hematologist-oncologists** (primary) — Prescribe TAVALISSE and REZLIDHIA for patients with chronic ITP or AML. - **Specialty pharmacy and wholesale channel partners** (primary) — Distribute commercial product to patients and support access and fulfillment. - **Pharmaceutical licensees and collaboration partners** (secondary) — Buy drug supply, pay royalties, and fund milestones under global agreements. - **Government and research counterparties** (secondary) — Provide contract funding for selected development or preparedness programs. - Hematologists treating chronic adult ITP in the U.S. - Hematologist-oncologists treating IDH1-mutated AML - Specialty pharmacies and wholesale distributors - Group purchasing organizations and reimbursement channels - Pharma partners buying rights, supply, or royalty-linked access ## Geography Rigel is headquartered in the United States and generates its direct commercial sales primarily in the U.S. through a physician-focused hematology sales force. It also has commercial and licensing activity outside the U.S. through partners in Europe, the UK, Japan, Korea, Canada, Israel, and other territories. Geography matters because the company’s revenue mix depends on U.S. product sales versus partner-driven international royalties, milestones, and supply revenue. - U.S. is the core commercial market for direct product sales - Europe and the UK are served through partnered commercialization - Japan, Korea, Canada, and Israel are key ex-U.S. markets for TAVALISSE - Partner agreements create international revenue without direct sales infrastructure - Geography affects reimbursement, regulatory access, and partner economics ## Strategy Rigel’s strategy is to commercialize its approved hematology products while extending their reach through licensing and regional partners. It also seeks to expand the value of its pipeline and partnered assets through development programs, regulatory approvals, and collaboration-based monetization. Patient access support and reimbursement services are part of the commercial model because they help convert prescriptions into realized sales. - **Defend and expand commercial uptake of TAVALISSE** (short-term) — The product is a core revenue driver and depends on specialist prescribing and access. - **Build REZLIDHIA as a second commercial asset** (medium-term) — A second approved product diversifies disease exposure and revenue sources. - **Monetize global rights through partnerships** (medium-term) — Licensing and supply agreements extend reach without requiring full direct infrastructure. - Grow U.S. adoption of TAVALISSE through focused hematology promotion - Support REZLIDHIA commercialization in AML through specialist prescribers - Use licensing partners to monetize ex-U.S. markets - Capture royalties, milestones, and drug supply revenue from collaborations - Maintain patient access support to reduce prescription friction ## Risks Rigel depends on a small number of products and disease areas, so demand shortfalls, competitive therapies, or generic entry could materially affect revenue. The business also relies on third-party manufacturers, distributors, and collaboration partners, which creates supply-chain and execution risk across both commercial and development activities. Because reimbursement and patient access are central to prescription conversion, changes in payer policy, rebates, or support-program economics can also pressure realized sales. - **Product concentration** [high] — A limited commercial portfolio means setbacks in one product can disproportionately affect revenue. - **Generic and competitive pressure** [high] — Specialty pharmaceuticals face branded and generic competition that can compress demand and pricing. - **Supply chain and third-party dependence** [medium] — The company relies on outside manufacturers, distributors, and logistics providers to deliver product. - **Partner and licensing execution** [medium] — International revenue depends on counterparties meeting commercialization, supply, and milestone obligations. - **Reimbursement and access pressure** [high] — Net sales depend on payer coverage, rebates, chargebacks, and patient assistance economics. - Concentrated dependence on TAVALISSE and REZLIDHIA - Generic or competing therapies could reduce product demand - Third-party manufacturing and logistics disruptions can interrupt supply - Partner execution risk affects royalties, milestones, and ex-U.S. sales - Rebate, chargeback, and patient support programs can reduce net sales ## Accounting Rigel’s revenue recognition is judgmental because product sales are recorded net of rebates, chargebacks, returns, and other variable consideration. Collaboration revenue can include upfront fees, milestones, royalties, and non-cash items, which may be recognized at different times depending on contract terms and performance obligations. Investors should also watch valuation allowances on deferred tax assets and estimates tied to inventory, receivables, and deferred revenue from partner agreements. - **Variable consideration in product sales** — Affects reported revenue and gross-to-net realization - **Collaboration revenue recognition** — Can create lumpy quarterly revenue - **Deferred revenue from partner agreements** — Impacts timing of reported revenue - **Valuation allowance on deferred tax assets** — Can materially affect tax expense and equity - Net product revenue depends on estimates for rebates and chargebacks - Specialty pharmacy and distributor data drive sales deductions - Collaboration revenue may include milestones, royalties, and upfront fees - Non-cash collaboration items can create period-to-period volatility - Deferred tax assets and valuation allowance reflect cumulative losses --- *Last updated: 2026-04-29T04:52:12.949895+00:00*